Thermo Fisher Scientific Inc (NYSE:TMO) Supports Australia’s Annual Tour de Cure


Dallas, Texas 03/28/2014 (FINANCIALSTRENDS) – Thermo Fisher Scientific Inc (NYSE:TMO) announced that it is now a supporting Australia’s Annual Tour de Cure via sponsorship, fund-raising efforts & donation of the company’s Life Technologies Ion Torrent next-gen sequencing-solutions to the Tour de Cure to pass-on to the deserving recipients for many cancer research projects that have been selected by Tour de Cure. As a member of this community, the company is delighted to participate in this Tour de Cure that gives them chance to reach-out to even more people and also drive towards making this a much more manageable disease.

This year, the Tour de Cure has now selected the following 2 cancer research projects as the recipients of its donated Life Technologies products. The research project that is led by Professor Alexander Dobrovic, the Head of Translational Genomics and Epigenomics Laboratory, the Ludwig Institute for Cancer Research, will be receiving the Life Technologies Ion-Torrent Proton System and The project that is led by the Professor John Rasko AO, the Head of the Gene & Stem Cell Therapy Program, the Centenary Institute of Cancer Medicine and Cell Biology, will also receive the Life Technologies Ion-Torrent PGM System.

Both these  instruments play very key roles in genetic analysis work- flow to help cancer researchers with much better identification of the cancer types and they will be donated in the  package including some other resources that also supports this research. These 2 research projects will now be introduced on 29 March at Tour de Cure’s Community Celebration Dinner-event at Canberra. Tour de Cure is the non-profit-making-organization that is dedicated to finding the cure for cancer via awareness & raising funds for cancer-prevention & research projects with the 1,576km-distance long signature tour. In 2014, 111 participants will be cycling right from Sydney up to Hobart starting 28 March to 6 April 2014.